Cereno Scientific

Cereno Scientific is advancing a pipeline that includes an HDACi portfolio with two drug candidates in clinical phase – CS1 in pulmonary arterial hypertension and CS014 in idiopathic pulmonary fibrosis. The HDACi portfolio has an innovative disease-modifying approach to addressing the root mechanism of rare and fatal diseases, untapping the potential of epigenetic modulation in rare cardiovascular and pulmonary diseases. In preclinical stage, our drug candidate CS585, a novel prostacyclin (IP) receptor agonist, has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular disease. Cereno Scientific has the potential to deliver high treatment value to people that are suffering from rare cardiovascular and pulmonary diseases who today have unmet medical needs.